COX-2 inhibition and colorectal cancer

Seminars in Oncology

Volumn 31, Issue SUPPL. 7, 2004, Pages 12-21

  Koehne, Claus Henning ^b   Dubois, Raymond N ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIINFECTIVE AGENT; CAPECITABINE; CELECOXIB; CYCLOOXYGENASE 2; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; INDOMETACIN; IRINOTECAN; MECLOFENAMIC ACID; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; PACLITAXEL; PELITINIB; PERTUZUMAB; PIROXICAM; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN INHIBITOR; ROFECOXIB; SULINDAC; TAXANE DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADENOMATOUS POLYP; ANTIINFLAMMATORY ACTIVITY; BLEEDING; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER THERAPY; CLINICAL TRIAL; COLORECTAL CANCER; CYTOKINE PRODUCTION; DESMOID TUMOR; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; HAND FOOT AND MOUTH DISEASE; HUMAN; INFLAMMATION; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUTROPENIA; NONHUMAN; PHLEBITIS; POLYP; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STOMATITIS;

ADENOMATOUS POLYPOSIS COLI; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; SULFONAMIDES; SULINDAC;

EID: 3042788940     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.seminoncol.2004.03.041     Document Type: Review

References (29)

1. Mann M., Sheng H., Shao J., et al. Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology. 120:2001;1713-1719
2. DuBois R.N., Giardiello F.M., Smalley W.E. Nonsteroidal anti-inflammatory drugs, eicosanoids, and colorectal cancer prevention. Gastroenterol Clin North Am. 25:1996;773-791
3. DuBois R.N., Abramson S.B., Crofford L., et al. Cyclooxygenase in biology and disease. FASEB J. 12:1998;1063-1073
4. Isakson P., Seibert K., Masferrer J., et al. Discovery of a better aspirin. Adv Prostaglandin Thromboxane Leukot Res. 23:1995;49-54
5. Masferrer J.L., Leahy K.M., Koki A.T., et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 60:2000;1306-1311
6. Sheng H., Shao J., Kirkland S.C., et al. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest. 99:1997;2254-2259
7. Silverstein F.E., Faich G., Goldstein J.L., et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS Study: A randomized controlled trial. JAMA. 284:2000;1247-1255
8. Δ716 knockout mice by inhibition of cyclooxygenase 2(COX-2). Cell. 87:1996;803-809
9. Waddell W.R., Ganser G.F., Cerise E.J., et al. Sulindac for polyposis of the colon. Am J Surg. 157:1989;175-179
10. Williams C.S., Tsujii M., Reese J., et al. Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest. 105:2000;1589-1594
11. Williams C., Shattuck-Brandt R.L., DuBois R.N. The role of COX-2 in intestinal cancer. Ann NY Acad Sci. 889:1999;72-83
12. 2. Cancer Res. 61:2001;81-87
13. 1 in colon carcinogenesis. Cancer Res. 59:1999;5093-5096
14. Δ716 knockout mice. Nat Med. 9:2001;1048-1051
15. Dannenberg A.J., Altorki N.K., Boyle N.O., et al. Cyclo-oxygenase 2 A pharmacological target for the prevention of cancer. Lancet Oncol. 2:2001;544-551
16. Dormond O., Foletti A., Paroz C., et al. NSAIDs inhibit αVβ3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis. Nat Med. 9:2001;1041-1047
17. Jones M.K., Wang H., Peskar B.M., et al. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs Insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med. 5:1999;1418-1423
18. 2 in human colon cancer cells. Cancer Res. 58:1998;362-366
19. 2 increases growth and motility of colorectal carcinoma cells. J Biol Chem. 21:2001;18075-18081
20. Giardiello F.M., Hamilton S.R., Krush A.J., et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med. 328:1993;1313-1316
21. Steinbach G., Lynch P.M., Phillips R.K.S., et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 342:2000;1946-1952
22. Physicians' Desk Reference. 2003;Thomson PDR, Montvale, NJ. (Celebrex: page 2590)
23. Torrance C.J., Jackson P.E., Montgomery E., et al. Combinatorial chemoprevention of intestinal neoplasia. Nat Med. 6:2000;1024-1028
24. Trifan O.C., Durham W.F., Salazar V.S., et al. Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11. Cancer Res. 62:2002;5778-5784
25. Lin E.H., Morris J., Chau N.K., et al. Celecoxib attenuated capecitabine induced hand-and-foot syndrome (HFS) and diarrhea and improve time to tumor progression in metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol. 21:2002;138b. (abstr 2364)
26. Becerra C.R., Frenkel E.P., Gaynor R. A phase II study of 5-fluorouracil (5-FU) and leucovorin calcium (LV) plus open-label Rofecoxib in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol. 21:2002;107b. (abstr 2240)
27. Blanke C.D., Benson A.B., Dragovich T., et al. A phase II trial of celecoxib (CX), irinotecan (I), 5-fluorouracil (5FU), and leucovorin (LCV) in patients (pts) with unresectable or metastatic colorectal cancer (CRC). Proc Am Soc Clin Oncol. 21:2002;127a. (abstr 505)
28. Sweeney C., Seitz D., Ansari R., et al. A phase II trial of irinotecan (I), 5-fluorouracil (F), leucovorin (L) (IFL), celecoxib and glutamine as first line therapy for advanced colorectal cancer A Hoosier Oncology Group study. Proc Am Soc Clin Oncol. 21:2002;105b. (abstr 2235)
29. Pan C., Loehrer P., Juliar B., et al. A phase II trial of irinotecan (I), 5-fluorouracil (F), leucovorin (L) (IFL), celecoxib and glutamine as first line therapy for advanced colorectal cancer (CRC) A Hoosier Oncology Group Study. Proc Am Soc Clin Oncol. 22:2003;335. (abstr 1347)